Amicus Therapeutics' GAAP loss for 3 months of 2022 was $85.26 million, up 29.8% from $65.664 million in the prior year. Revenue increased 18.5% to $78.715 million from $66.402 million a year earlier.
Amicus Therapeutics' GAAP loss for 3 months of 2022 was $85.26 million, up 29.8% from $65.664 million in the prior year. Revenue increased 18.5% to $78.715 million from $66.402 million a year earlier. 
ir.amicusrx.com
English (US) 